Abstract
The fibrosarcoma MCA‐SP, which was recently induced with methylcholanthrene (MCA) in C3H/ HeJ mice, displays poor immunogenicity in in vivo prophylaxis. A cell variant MCA‐SPN1, which bears a tumor‐specific transplantation antigen (TSTA) cross‐reactive with the parental line MCA‐SP, was selected because of its proclivity for axillary lymph‐node metastases. Although these lymph‐node metastases were resistant to sinecomitant (post‐excisional) immunity, they were susceptible to combined active and passive specific Chemoimmunotherapy, using tumor‐specific, 1‐butanol‐extracted, preparative isoelectric focusing‐purified, TSTA (1 fig weekly sc injections), cyclophosphamide (CY, a single intraperitoneal 20 mg/kg dose), and adoptive transfer of immune splenic T lymphocytes, which had been re‐stimulated in vitro with extracted TSTA and interleukin‐2. This triple regimen both reduced the incidence of spontaneous lymph‐node metastases, and prolonged the survival of tumor‐bearing, as well as tumor‐resected hosts. The results from local adoptive transfer assay using T‐lymphocyte snbpopulations of spleen and lymph nodes in these treated hosts suggested that Lyt 2+ cytotoxic T‐lymphocytes (CTL) mediated in vivo tumor‐neutralization. Thus TSTA/CY/CTL therapy activates tumoricidal host responses effective against the poorly immunogenic MCA‐SP tumor and its lymph‐node metastases.
Keywords: Active specific Chemoimmunotherapy, Tumor antigen, Murine fibrosarcoma, Lymph‐node metastasis
Full Text
The Full Text of this article is available as a PDF (468.4 KB).
REFERENCES
- 1. ) Baldwin , R. W.Immunological aspects of chemical carcinogenesis . Adv. Cancer Res. , 18 , 1 – 76 ( 1973. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Pellis , N. R. , Tom , B. H. and Kahan , B. D.Tumor specific and allospecific immunogenicity of soluble extracts from chemically induced marine sarcomas . J. Immunol , 113 , 708 – 711 ( 1974. ). [PubMed] [Google Scholar]
- 3. ) LeGrue , S. J. , Kahan , B. D. and Pellis , N. R.Extraction of a murine tumor‐specific transplantation antigen with 1‐butanol: I. Partial purification by isoelectric focusing . J. Natl. Cancer Inst. , 65 , 1001 – 1004 ( 1980. ). [PubMed] [Google Scholar]
- 4. ) LeGrue , S. J. , Pellis , N. R. , Riley , L. B. and Kahan , B. D.Biochemical characterization of 1‐butanol‐extracted murine tumor‐specific transplantation antigens . Cancer Res. , 45 , 3164 – 3271 ( 1985. ). [PubMed] [Google Scholar]
- 5. ) Pellis , N. R. and Kahan , B. D.Specific tumor immunity induced with soluble materials irestricted range of antigen dose and of challenge tumor load for immunoprotection J. Immunol , 115 , 1717 – 1722 ( 1975. ). [PubMed] [Google Scholar]
- 6. ) Macek , C. M. , Kahan , B. D. and Pellis , N. R.Delayed hypersensitivity to crude and partially purified murine tumor‐specific transplantation antigens and alloantigens utilizing the footpad swelling assay . J. Immunol , 125 , 1639 – 1643 ( 1980. ). [PubMed] [Google Scholar]
- 7. ) Fujimoto , S. , Green , M. I. , and Sehon , A. M.Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor‐bearing hosts . J. Immunol , 116 , 791 – 799 ( 1976. ). [PubMed] [Google Scholar]
- 8. ) Rao , V. S. and Bonavida , B.Specific enhancement of tumor growth and depression of cell‐mediated immunity following sensitization to soluble tumor antigens . Cancer Res. , 36 , 1384 – 1391 ( 1976. ). [PubMed] [Google Scholar]
- 9. ) North , R. J.Cyclophosphamide‐facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor induced suppressor T cells . J. Exp. Med. , 155 , 1063 – 1074 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. ) Digiacomo , A. and North , R. J.T cell suppressors of anti‐tumor immunity: the production of Ly‐l−, 2+ suppressor of delayed sensitivity precedes the production of suppressors of protective immunity . J. Exp. Med. , 164 , 1179 – 1192 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. ) Kahan , B. D. , Pellis , N. R. , LeGrue , S. J. and Tanaka , T.Immunotherapeutic effects of tumor‐specific transplantation antigens released by 1‐butanol . Cancer , 49 , 1168 – 1173 ( 1982. ). [DOI] [PubMed] [Google Scholar]
- 12. ) Nomi , S. , Pellis , N. R. and Kahan , B. D.Retardation of post‐surgical metastases with the use of extracted tumorspecific transplantation antigens and cyclophosphamide . J. Natl. Cancer Inst. , 73 , 943 – 950 ( 1984. ). [PubMed] [Google Scholar]
- 13. ) Naito , K. , Pellis , N. R. and Kahan , B. D.Expansion of tumor‐specific cytolytic T lymphocytes using in vitro restimulation with tumor‐specific transplantation antigens . Cell. Immunol , 108 , 483 – 494 ( 1987. ). [DOI] [PubMed] [Google Scholar]
- 14. ) Fidler , I. J.Selection of successive tumor lines for metastasis . Nature (New Biol) , 242 , 148 – 149 ( 1974. ). [DOI] [PubMed] [Google Scholar]
- 15. ) Bradford , M. M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein‐dye binding . Anal. Biochem. , 72 , 248 – 254 ( 1976. ). [DOI] [PubMed] [Google Scholar]
- 16. ) Rong , G. H. , Grimm , E. A. and Sinderlar , W. F.An enzymatic method for the consistent production of monodispersed viable cell suspensions from human solid tumors . J. Surg. Oncol , 28 , 131 – 133 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 17. ) Pellis , N. R. and Kahan , B. D.Methods to demonstrate the immunogenicity of soluble tumor‐specific transplantation antigens: II. The local adoptive transfer assay . Methods Cancer Res. , 14 , 29 – 54 ( 1978. ). [Google Scholar]
- 18. ) Nomi , S. , Naito , K. , Kahan , B. D. and Pellis , N. R.Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice . Cancer Res. , 46 , 6111 – 6115 ( 1986. ). [PubMed] [Google Scholar]
- 19. ) Smith , H. G. , Harmel , R. P. , Hanna , M. G. , Jr. , Zwilling , B. S. , Zbar , B. and Rapp , H. J.Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells . J. Natl. Cancer Inst. , 58 , 1315 – 1321 ( 1977. ). [DOI] [PubMed] [Google Scholar]
- 20. ) Greenberg , P. D. , Cheever , M. A. and Fefer , A.Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt l+2− lymphocytes . J. Exp. Med. , 151 , 69 – 80 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. ) Fernandez‐Cruz , E. , Gilman , S. C. and Feldman , J. D.Immunotherapy of a chemically‐induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression . J. Immunol. , 128 , 1112 – 1117 ( 1982. ). [PubMed] [Google Scholar]
- 22. ) Evans , R.Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor sensitized T lymphocytes: potential mechanisms of action . Int. J. Cancer , 33 , 381 – 388 ( 1984. ). [DOI] [PubMed] [Google Scholar]
- 23. ) Greenberg , P. D.Therapy of murine leukemia with cyclophosphamide and immune Lyt 2+ T cells: cytolytic T cells can mediate eradication of desseminated leukemia . J. Immunol. , 136 , 1917 – 1922 ( 1986. ). [PubMed] [Google Scholar]
- 24. ) Yamasaki , T. , Handa , H. , Yamashita , J. , Watanabe , Y. and Hanaoka , M.Specific adoptive immunotherapy with tumor specific cytotoxic T‐lymphocyte clone for murine malignant gliomas . Cancer Res. , 44 , 1976 – 1980 ( 1984. ). [PubMed] [Google Scholar]
- 25. ) Matis , L. A. , Shu , S. , Groves , .E. S. , Zinn , S. , Chou , T. , Kruisbeck , A. M. , Rosenstein , M. and Rosenberg , S. A.Adoptive immunotherapy of a syngeneic murine leukemia with a tumor‐specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL‐2 receptor expression . J. Immunol. , 136 , 3496 – 3501 ( 1986. ). [PubMed] [Google Scholar]
- 26. ) Shu , S. and Rosenberg , S. A.Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells . J. Immunol , 135 , 2895 – 2903 ( 1985. ). [PubMed] [Google Scholar]